Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- COVID-19 (2)
- SARS-CoV-2 (2)
- Aerosols (1)
- Airborne pathogens (1)
- Antiviral agents (1)
-
- Bacteria (1)
- Bioluminescence (1)
- COVID-19 vaccines (1)
- COVID-19/therapy (1)
- Communicable disease control (1)
- Coronavirus infection (1)
- Epidemic (1)
- HEPA filters (1)
- Hospital mortality (1)
- ICU (1)
- Immunization (1)
- Infectious disease transmission (1)
- Laboratory testing (1)
- Messenger RNA (1)
- Microbiology (1)
- PACU (1)
- Pandemic (1)
- Patient safety (1)
- Remdesivir (1)
- Respiratory tract infections (1)
- Retrospective study (1)
- Treatment outcome (1)
- Vaccines (1)
- Ventilation (1)
- Viral vaccines/adverse effects (1)
Articles 1 - 3 of 3
Full-Text Articles in Viruses
Laboratory Study Of A Waste Anesthetic Gas Mask Scavenging System To Reduce Airborne Pathogen Exposure For Health Care Workers In Post Anesthesia Care Units, Josh Horton, Trevor Lim, Andrew Kanach, John Moenning, James Mcglothlin, Bruce M. Applegate Sr.
Laboratory Study Of A Waste Anesthetic Gas Mask Scavenging System To Reduce Airborne Pathogen Exposure For Health Care Workers In Post Anesthesia Care Units, Josh Horton, Trevor Lim, Andrew Kanach, John Moenning, James Mcglothlin, Bruce M. Applegate Sr.
HCA Healthcare Journal of Medicine
Introduction
A scavenging oxygen mask system (SOMS) utilizing house vacuum has been demonstrated to significantly reduce exposure of post anesthesia care unit (PACU) health care workers (HCWs) to waste anesthetic gases (WAGs). Therefore, it was proposed that the same system could also be used to protect HCWs in the PACU by reducing Infectious Respiratory Particles (IRPs) spread from patients who may harbor airborne infective pathogens, such as Mycobacterium tuberculosis, certain strains of influenza, and SARS-CoV-2.
Methods
A life-like adult manikin head equipped with a bio-aerosol Collison nebulizer was set up to simulate patients exhausting pathogenic droplets. Further evaluation of …
Evaluation Of The Efficacy Of Remdesivir For The Treatment Of Coronavirus Disease 2019, Alexandra Flannery, Anastasia Knecht, Koravangala Sundaresh
Evaluation Of The Efficacy Of Remdesivir For The Treatment Of Coronavirus Disease 2019, Alexandra Flannery, Anastasia Knecht, Koravangala Sundaresh
HCA Healthcare Journal of Medicine
Background
Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus, SARS-CoV-2, has accounted for more than 1 000 000 deaths in the United States alone. In May 2020, the Food and Drug Administration issued an Emergency Use Authorization to allow the investigational use of intravenous remdesivir for the treatment of suspected or confirmed COVID-19 in hospitalized children and adults. Several other agents, such as hydroxychloroquine, dexamethasone, and tocilizumab have been investigated as potential treatment options; however, dexamethasone is currently the only agent that has been proven to reduce mortality in patients who require supplemental oxygen. The purpose of this study …
Covid-19: Race For Vaccine, L. Hayley Burgess, Jason J. Braithwaite, Emily Singleton, Aaron M. Young, Mandelin K. Cooper
Covid-19: Race For Vaccine, L. Hayley Burgess, Jason J. Braithwaite, Emily Singleton, Aaron M. Young, Mandelin K. Cooper
HCA Healthcare Journal of Medicine
The world is in the midst of a pandemic from COVID-19, a disease caused by the virus SARS-CoV-2. Despite broad mitigation efforts, new cases continue with 74 million cases and 1.6 million deaths worldwide. Regardless of previous research efforts, there is no commercially available vaccine for any coronavirus. Novel vaccine development has historically taken at least 10 years from discovery to availability with only a 6% market entry probability.
With the global impact, there is an urgency to expedite a vaccine to protect the population. The U.S. government launched Operation Warp Speed with the goal to produce and deliver 300 …